Literature DB >> 23072752

Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain.

Isaac Marin-Valencia1, Levi B Good, Qian Ma, Craig R Malloy, Juan M Pascual.   

Abstract

It has been postulated that triheptanoin can ameliorate seizures by supplying the tricarboxylic acid cycle with both acetyl-CoA for energy production and propionyl-CoA to replenish cycle intermediates. These potential effects may also be important in other disorders associated with impaired glucose metabolism because glucose supplies, in addition to acetyl-CoA, pyruvate, which fulfills biosynthetic demands via carboxylation. In patients with glucose transporter type I deficiency (G1D), ketogenic diet fat (a source only of acetyl-CoA) reduces seizures, but other symptoms persist, providing the motivation for studying heptanoate metabolism. In this work, metabolism of infused [5,6,7-(13)C(3)]heptanoate was examined in the normal mouse brain and in G1D by (13)C-nuclear magnetic resonance spectroscopy, gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS). In both groups, plasma glucose was enriched in (13)C, confirming gluconeogenesis from heptanoate. Acetyl-CoA and glutamine levels became significantly higher in the brain of G1D mice relative to normal mice. In addition, brain glutamine concentration and (13)C enrichment were also greater when compared with glutamate in both animal groups, suggesting that heptanoate and/or C5 ketones are primarily metabolized by glia. These results enlighten the mechanism of heptanoate metabolism in the normal and glucose-deficient brain and encourage further studies to elucidate its potential antiepileptic effects in disorders of energy metabolism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072752      PMCID: PMC3564188          DOI: 10.1038/jcbfm.2012.151

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  39 in total

1.  Analysis of the citric acid cycle intermediates using gas chromatography-mass spectrometry.

Authors:  Rajan S Kombu; Henri Brunengraber; Michelle A Puchowicz
Journal:  Methods Mol Biol       Date:  2011

2.  High-resolution detection of ¹³C multiplets from the conscious mouse brain by ex vivo NMR spectroscopy.

Authors:  Isaac Marin-Valencia; Levi B Good; Qian Ma; F Mark Jeffrey; Craig R Malloy; Juan M Pascual
Journal:  J Neurosci Methods       Date:  2011-09-17       Impact factor: 2.390

Review 3.  Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis.

Authors:  Isaac Marin-Valencia; Charles R Roe; Juan M Pascual
Journal:  Mol Genet Metab       Date:  2010-06-09       Impact factor: 4.797

4.  Brain glutamine synthesis requires neuronal-born aspartate as amino donor for glial glutamate formation.

Authors:  Beatriz Pardo; Tiago B Rodrigues; Laura Contreras; Miguel Garzón; Irene Llorente-Folch; Keiko Kobayashi; Takeyori Saheki; Sebastian Cerdan; Jorgina Satrústegui
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

5.  Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype.

Authors:  Isaac Marin-Valencia; Levi B Good; Qian Ma; Joao Duarte; Teodoro Bottiglieri; Christopher M Sinton; Charles W Heilig; Juan M Pascual
Journal:  Neurobiol Dis       Date:  2012-04-23       Impact factor: 5.996

Review 6.  Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?

Authors:  Karin Borges; Ursula Sonnewald
Journal:  Epilepsy Res       Date:  2011-08-19       Impact factor: 3.045

7.  Adult Polyglucosan Body Disease (APBD): Anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways.

Authors:  Charles R Roe; Teodoro Bottiglieri; Mary Wallace; Erland Arning; Alan Martin
Journal:  Mol Genet Metab       Date:  2010-07-06       Impact factor: 4.797

8.  Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models.

Authors:  Sarah Willis; James Stoll; Lawrence Sweetman; Karin Borges
Journal:  Neurobiol Dis       Date:  2010-08-04       Impact factor: 5.996

9.  Cortical metabolism in pyruvate dehydrogenase deficiency revealed by ex vivo multiplet (13)C NMR of the adult mouse brain.

Authors:  Isaac Marin-Valencia; Levi B Good; Qian Ma; Craig R Malloy; Mulchand S Patel; Juan M Pascual
Journal:  Neurochem Int       Date:  2012-08-03       Impact factor: 3.921

10.  Catabolism of 4-hydroxyacids and 4-hydroxynonenal via 4-hydroxy-4-phosphoacyl-CoAs.

Authors:  Guo-Fang Zhang; Rajan S Kombu; Takhar Kasumov; Yong Han; Sushabhan Sadhukhan; Jianye Zhang; Lawrence M Sayre; Dale Ray; K Michael Gibson; Vernon A Anderson; Gregory P Tochtrop; Henri Brunengraber
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

View more
  31 in total

Review 1.  New insights into the mechanisms of the ketogenic diet.

Authors:  Detlev Boison
Journal:  Curr Opin Neurol       Date:  2017-04       Impact factor: 5.710

2.  Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).

Authors:  Jerry Vockley; Barbara Burton; Gerard T Berry; Nicola Longo; John Phillips; Amarilis Sanchez-Valle; Pranoot Tanpaiboon; Stephanie Grunewald; Elaine Murphy; Alexandra Bowden; Wencong Chen; Chao-Yin Chen; Jason Cataldo; Deborah Marsden; Emil Kakkis
Journal:  J Inherit Metab Dis       Date:  2019-01       Impact factor: 4.982

3.  Triheptanoin alters [U-13C6]-glucose incorporation into glycolytic intermediates and increases TCA cycling by normalizing the activities of pyruvate dehydrogenase and oxoglutarate dehydrogenase in a chronic epilepsy mouse model.

Authors:  Tanya McDonald; Mark P Hodson; Ilya Bederman; Michelle Puchowicz; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2019-03-19       Impact factor: 6.200

4.  Tridecanoin is anticonvulsant, antioxidant, and improves mitochondrial function.

Authors:  Kah Ni Tan; Catalina Carrasco-Pozo; Tanya S McDonald; Michelle Puchowicz; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 5.  Modification of Astrocyte Metabolism as an Approach to the Treatment of Epilepsy: Triheptanoin and Acetyl-L-Carnitine.

Authors:  Mussie Ghezu Hadera; Tanya McDonald; Olav B Smeland; Tore W Meisingset; Haytham Eloqayli; Saied Jaradat; Karin Borges; Ursula Sonnewald
Journal:  Neurochem Res       Date:  2015-10-03       Impact factor: 3.996

6.  Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement.

Authors:  Juan M Pascual; Peiying Liu; Deng Mao; Dorothy I Kelly; Ana Hernandez; Min Sheng; Levi B Good; Qian Ma; Isaac Marin-Valencia; Xuchen Zhang; Jason Y Park; Linda S Hynan; Peter Stavinoha; Charles R Roe; Hanzhang Lu
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

Review 7.  Short- and medium-chain fatty acids in energy metabolism: the cellular perspective.

Authors:  Peter Schönfeld; Lech Wojtczak
Journal:  J Lipid Res       Date:  2016-04-14       Impact factor: 5.922

Review 8.  Alternative Fuels in Epilepsy and Amyotrophic Lateral Sclerosis.

Authors:  Tesfaye W Tefera; Kah Ni Tan; Tanya S McDonald; Karin Borges
Journal:  Neurochem Res       Date:  2016-11-21       Impact factor: 3.996

9.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Authors:  Jeremy S Francis; Vladimir Markov; Paola Leone
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

10.  Differential effects of octanoate and heptanoate on myocardial metabolism during extracorporeal membrane oxygenation in an infant swine model.

Authors:  Masaki Kajimoto; Dolena R Ledee; Aaron K Olson; Nancy G Isern; Christine Des Rosiers; Michael A Portman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-07-31       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.